Computational design of protein binders that boost the antitumour efficacy of CAR T cells

IF 26.8 1区医学 Q1 ENGINEERING, BIOMEDICAL

Nature Biomedical Engineering Pub Date : 2024-10-24 DOI:10.1038/s41551-024-01263-x

引用次数: 0

Abstract

We computationally designed protein binders for chimeric antigen receptor (CAR) constructs to target the glioblastoma-associated antigens EGFR and CD276. Compared with standard CAR T cells, CAR T cells with the de novo-designed binders showed enhanced proliferation, cytokine release and resistance to exhaustion, as well as superior antitumour effects in vitro and in vivo.

Abstract Image

查看原文本刊更多论文

通过计算设计可提高 CAR T 细胞抗肿瘤功效的蛋白质结合剂

我们通过计算设计了嵌合抗原受体（CAR）构建体的蛋白结合体，以靶向胶质母细胞瘤相关抗原表皮生长因子受体（EGFR）和CD276。与标准的CAR T细胞相比，带有全新设计的结合剂的CAR T细胞在体外和体内的增殖、细胞因子释放和抗衰竭能力都有所增强，抗肿瘤效果也更出色。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Biomedical Engineering Medicine-Medicine (miscellaneous)

CiteScore

45.30

自引率

1.10%

发文量

138

期刊介绍： Nature Biomedical Engineering is an online-only monthly journal that was launched in January 2017. It aims to publish original research, reviews, and commentary focusing on applied biomedicine and health technology. The journal targets a diverse audience, including life scientists who are involved in developing experimental or computational systems and methods to enhance our understanding of human physiology. It also covers biomedical researchers and engineers who are engaged in designing or optimizing therapies, assays, devices, or procedures for diagnosing or treating diseases. Additionally, clinicians, who make use of research outputs to evaluate patient health or administer therapy in various clinical settings and healthcare contexts, are also part of the target audience.